Insulin pump in type 2 diabetes: B-cell focused treatment

Česká verze

Authors: Klára Picková; Zdeněk Rušavý
Authors place of work: I. interní klinika LF UK a FN Plzeň
Published in the journal: Vnitř Lék 2017; 63(6): 441-445
Category: Přehledné referáty

Summary

Type 2 diabetes is a disorder characterized by insulin resistance and progressive deterioration of B-cell insulin secretion. B-cell protective strategies for lowering glucolipotoxicity by rapid achievement of normoglycemia using exogenous insulin improve their function and prolong diabetes remission. Insulin pump is an effective treatment method in newly diagnosed diabetes, where even short-term pump therapy is B-cell protective. Combination therapy with insulin pump and antidiabetics targeting the incretin system acts in synergy to protect the B-cell. While the positive effect of insulin pump is apparent even a year after stopping the therapy, the effect of incretins lasts only while on the medication. Short-term insulin treatment, especially delivered by insulin pump, is an effective method of B-cell protection in recent type 2 diabetes.

Key words:
B-cell function – diabetes mellitus – insulin pump – insulin resistance – type 2 diabetes

Zdroje

1. Reznik Y Continuous subcutaneous insulin infusion (CSII) using an external insulin pump for the treatment of type 2 diabetes. Diabetes Metab 2010; 36(6 Pt 1): 415–421. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabet.2010.08.002>.

2. Tabak AG, Jokela M, Akbaraly TN et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373(9682): 2215–2221. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(09)60619-X>.

3. Bensellam M, Laybutt DR, Jonas JC. The molecular mechanisms of pancreatic β-cell glucotoxicity: Recent findings and future research directions. Mol Cell Endocrinol 2012; 364(1–2):1–27. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mce.2012.08.003>.

4. Back SH, Kaufman RJ. Endoplasmic Reticulum Stress and Type 2 Diabetes. Annu Rev Biochem 2012; 81: 767–793. Dostupné z DOI: <http://dx.doi.org/10.1146/annurev-biochem-072909–095555>.

5. Poitout V, Robertson RP. Glucolipotoxicity: Fuel Excess and β-Cell Dysfunction. Endocr Rev 2008; 29(3): 351–366. Dostupné z DOI: <https://doi.org/10.1210/er.2007–0023>.

6. Poitout V, Amyot J, Semache M et al. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2010;1801(3): 289–298. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bbalip.2009.08.006>.

7. Marzban L. New Insights Into the Mechanisms of Islet Inflammation in Type 2 Diabetes: Figure 1. Diabetes [online] 2015; 64(4): 1094–1096. Dostupné z DOI: <http://dx.doi.org/10.2337/db14–1903>.

8. Schwartz SS, Epstein S, Corkey BE et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema. Diabetes Care [online] 2016; 39(2): 179–186. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15–1585>.

9. Matveyenko AV, Butler PC. Relationship between β-cell mass and diabetes onset. Diabetes Obes Metab 2008 Nov;10 Suppl 4:23–31. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1463–1326.2008.00939.x>.

10. Meier JJ, Bonadona RC. Role of Reduced-Cell Mass Versus Impaired-Cell Function in the Pathogenesis of Type 2 Diabetes. Diabetes Care 2013; 36(Suppl2): S113-S119. Dostupné z DOI: <http://dx.doi.org/10.2337/dcS13–2008>.

11. Defronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes Care 2013; 36(Suppl 2): S127-S138. Dostupné z DOI: <http://dx.doi.org/10.2337/dcS13–2011>.

12. Weng J, Yanbing LI, Wen XU et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371(9626): 1753–1760. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(08)60762-X>.

13. Škrha J. Doporučený postup péče o diabetes mellitus 2. typu. DMEV 2016; 19(2): 48–56.

14. Khunti K, Wolden ML, Thorsted BL et al. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. Diabetes Care 2013; 36(11): 3411–3417. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13–0331>.

15. Zeng L, Lu H, Deng H et al. Noninferiority Effects on Glycemic Control and β-Cell Function Improvement in Newly Diagnosed Type 2 Diabetes Patients: Basal Insulin Monotherapy Versus Continuous Subcutaneous Insulin Infusion Treatment. Diabetes Technol Ther 2012; 14(1): 35–42. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2011.0123>.

16. Retnakaran R, Zinman B. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function. Diabetes Obes Metab 2012; 14(Suppl 3): S161–S166. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1463–1326.2012.01658.x>.

17. Reznik Y, Cohen O. Insulin Pump for Type 2 Diabetes: Use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes. Diabetes Care 2013; 36(Suppl 2): S219-S225. Dostupné z DOI: <http://dx.doi.org/10.2337/dcS13–2027>.

18. Reznik Y, Cohen O, Aronson R et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet 2014; 384(9950): 1265–1272. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(14)61037–0>.

19. Choi SB, Lee JH, Kim S et al. Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control. Diabetes Metab Res Rev 2013; 29(6): 473–482. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.2416>.

20. Retnakaran R, Kramer CK, Choi H et al. Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 2014; 37(12): 3270–3278. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14–0893>.

21. Ke W, Liu L, Liu J et al. Effects of Liraglutide Combined with Short-Term Continuous subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study. J Diabetes Res 2016; 2016: 6839735. Dostupné z DOI: <http://dx.doi.org/10.1155/2016/6839735>.

22. Lin CH, Hsieh SH, Sun JH et al. Glucose Variability and β- Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes. Sci Rep 2015; 5:16968. Dostupné z DOI: <http://dx.doi.org/10.1038/srep16968>.

23. Wan H, Zhao D, Shen J et al. Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. J Diabetes Res 2016; 2016: 9849328. Dostupné z DOI: <http://dx.doi.org/10.1155/2016/9849328>.

24. Yuan G, Jia J, Zhang C et al. Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes. Endocr J 2014; 61(5): 513–521. Dostupné z WWW: <https://www.jstage.jst.go.jp/article/endocrj/61/5/61_EJ13–0483/_pdf>.

25. Yuan G, Hu H, Wang S et al. Improvement of β-cell function ameliorated glycemic variability in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion or in combination with sitagliptin treatment: a randomized control trial. Endocr J 2015; 62(9): 817–834. Dostupné z DOI: <http://dx.doi.org/10.1507/endocrj.EJ15–0160>.